Femoral Artery Occlusion Clinical Trial
Official title:
Chansu Vascular Technologies Everolimus-Coated Balloon Percutaneous Transluminal Angioplasty Catheter First-in-Human Clinical Investigation
Verified date | February 2023 |
Source | Chansu Vascular Technologies |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The CVT-SFA Trial investigates the inhibition of restenosis using the CVT Everolimus-coated PTA Catheter in the treatment of de-novo occluded/ stenotic or re-occluded/restenotic superficial femoral or popliteal arteries.
Status | Active, not recruiting |
Enrollment | 76 |
Est. completion date | September 1, 2025 |
Est. primary completion date | February 3, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Subject must be at least 18 years of age. 2. Subject provides written informed consent prior to any clinical investigation related procedure, as approved by the appropriate Ethics Committee of the respective clinical site. 3. Subject must agree to undergo all clinical investigation plan-required follow-up visits and examinations. 4. Subjects with symptomatic leg ischemia who do not respond favorably to Exercise Therapy or with symptoms that impact significantly daily life, requiring treatment of SFA or popliteal (P1 segment) artery. 5. De novo or restenotic lesion(s) >70% within the SFA and popliteal arteries in a single limb which are =3 cm and =15 cm in cumulative total length (by visual estimation). Lesion must be at least 2 cm from any stented area. 6. Subject is willing to comply with the required follow up visits, testing schedule and medication regimen. 7. Successful wire crossing of lesion. 8. Target vessel reference diameter =4 mm and =6 mm (by visual estimation). 9. Target lesion(s) can be treated with a maximum of two (2) CVT Everolimus-coated PTA Catheters. 10. At least one patent (less than 50% stenosis) tibio-peroneal run-off vessel confirmed by baseline angiography or prior MR angiography or CT angiography. 11. Life expectancy >1 year 12. Rutherford classification of 2, 3 or 4. Exclusion Criteria: 1. Pregnant or lactating females. 2. Co-existing clinically significant aneurismal disease of the abdominal aorta, iliac or popliteal arteries. 3. Significant gastrointestinal bleeding or any coagulopathy that would contraindicate the use of anti-platelet therapy. 4. Known intolerance to study medications, everolimus or contrast agents. 5. Doubts in the willingness or capability of the subject to allow follow-up examinations. 6. Subject is actively participating in another investigational device or drug study. 7. History of hemorrhagic stroke within 3 months of procedure. 8. Previous or planned surgical or interventional procedure within 30 days of index procedure. 9. Prior vascular surgery of the target lesion. 10. Lesion length is <3 cm or >15 cm or there is no normal proximal arterial segment in which duplex ultrasound velocity ratios can be measured. 11. Known inadequate distal outflow. 12. Significant inflow disease. 13. Acute or sub-acute thrombus in target vessel. 14. Use of adjunctive therapies (i.e. laser, atherectomy, cryoplasty, scoring/cutting balloons, brachytherapy, lithotripsy). 15. Outflow arteries (distal popliteal, anterior or posterior tibial or peroneal arteries) with significant lesions (= 50% stenosis) may not be treated during the same procedure. 16. Treatment of the contralateral limb during the same procedure or within 30 days of the study procedure. 17. Rutherford classification of 0, 1, 5 or 6 18. Presence of prohibitive calcification that precludes adequate PTA treatment. 19. Subjects held in custody in an institution by official or court order. 20. Subject is not covered by any medical insurance coverage. |
Country | Name | City | State |
---|---|---|---|
France | Polyclinique Les Fleurs | Ollioules | |
France | Hôpital Paris Saint Joseph | Paris | |
France | Hôpital Nord Laennec - CHU de Nantes | Saint-Herblain | |
France | Clinique Pasteur | Toulouse | |
Germany | Jüdisches Krankenhaus Berlin | Berlin | |
Germany | Vivantes Klinikum Neukölln | Berlin | |
Germany | DIAKO Krankenhaus Flensburg | Flensburg | |
Germany | Romed Klinikum Rosenheim | Rosenheim |
Lead Sponsor | Collaborator |
---|---|
Chansu Vascular Technologies |
France, Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Freedom of Major Adverse Event (MAE) rate | Composite rate of cardiovascular death, index limb amputation and ischemia-driven target lesion revascularization (TLR). | 6 months post-procedure | |
Primary | Patency | Freedom from restenosis as determined by duplex ultrasonography (DUS) (peak systolic velocity ratio (PSVR) =2.4 or =50% stenosis) and freedom from ischemia-driven target lesion revascularization (TLR). | 6 months post procedure | |
Secondary | Rate of MAE | Composite rate of cardiovascular death, index limb amputation and ischemia-driven Target Lesion Revascularization (TLR). | One year post-procedure | |
Secondary | Patency | Freedom from clinically driven TLR and duplex ultrasonography detected restenosis (ultrasound peak systolic velocity ratio = 2.4 or stenosis =50%) | 12 months post procedure |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01947478 -
MDT-2113 Drug-Eluting Balloon vs. Standard PTA for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery and/or Proximal Popliteal Artery
|
N/A | |
Recruiting |
NCT03687983 -
Safety and Efficacy Study of GoldenFlow Peripheral Stent System
|
N/A | |
Completed |
NCT02720003 -
A Single Arm Trial Evaluating the BARD Lutonix Drug-Coated Balloon (LTX DCB) for Treatment of Femoropopliteal Arteries
|
N/A | |
Completed |
NCT02063672 -
Lutonix® Drug Coated Balloon vs. Standard Balloon Angioplasty for Treatment of Femoropopliteal In-Stent Restenosis
|
N/A | |
Completed |
NCT01816412 -
LEVANT Japan Clinical Trial
|
Phase 2 | |
Completed |
NCT01566461 -
IN.PACT Admiral Drug-Coated Balloon vs. Standard Balloon Angioplasty for the Treatment of Superficial Femoral Artery (SFA) and Proximal Popliteal Artery (PPA)
|
N/A | |
Completed |
NCT01412541 -
Moxy Drug Coated Balloon vs. Standard Balloon Angioplasty for the Treatment of Femoropopliteal Arteries
|
N/A | |
Recruiting |
NCT03683459 -
Safety and Efficacy Study of FemFlow Drug-Eluting Peripheral Balloon Catheter
|
N/A | |
Recruiting |
NCT03142347 -
Remote Endarterectomy vs Remote Endarterectomy + Drug Coated Balloon (DCB) Angioplasty in Patients With the Femoral Artery Occlusive Disease
|
N/A | |
Terminated |
NCT00810134 -
Bypass or Thurpass for Superficial Femoral Artery Occlusion? Scandinavian Thurpass Study
|
N/A | |
Completed |
NCT02013271 -
Lutonix® DCB for Treatment of Long Lesions in Femoropopliteal Arteries
|
||
Completed |
NCT04343196 -
Digital Variance Angiography in Diagnostic Angiographies for Effective Radiation Dose Reduction
|
N/A | |
Terminated |
NCT02813577 -
Lutonix Drug Coated Balloon for Treatment of Femoropopliteal Arteries in United States Females (CONFIRM)
|
N/A | |
Completed |
NCT03844724 -
Drug-eluting PTA Balloon Dilatation Catheter in the Treatment of Peripheral Artery Stenosis or Occlusion
|
N/A |